We wish to take issue with several statements made by Kerstjens et al in their recent paper (July 1994;49:652-6). We believe that their conclusion that there is no clear evidence of a detrimental effect of inhaled corticosteroids on bone metabolism is unsubstantiated by the results of their study. They were able to demonstrate a significant fall in osteocalcin levels after four weeks of inhaled corticosteroid treatment, which implies a reduction in bone formation. This fall was no longer evident after two years of treatment. A less benign interpretation of these results is that reduced bone formation occurred at the start of treatment,' resulting in a fall in bone density. At a later stage bone metabolism may have returned to its previous equilibrium; any bone loss may not have been rectified by a later increase in bone formation. Unfortunately it is impossible to put the authors' results into a clinical context because they importantly failed to measure bone density.
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A confounding factor in the interpretation of the effects of inhaled corticosteroids is the effect of courses of systemic corticosteroids. Some patients in study II of their paper must have received systemic corticosteroids yet we are given no information about this. It would be important to know whether the control and treated groups received equivalent doses of systemic corticosteroids over the 2-5 year study period.
The authors question the validity of osteocalcin measurements and suggest that measurement of serum levels of propeptide of type I collagen (PICP) may be a more valid marker of bone formation than osteocalcin (which was measured in our study). Nevertheless there is contrary evidence indicating that PICP may be a less sensitive marker of bone formation than osteocalcin.2
Our study on the effects of inhaled beclomethasone dipropionate on bone metabolism and density3 is referenced by Kerstjens et al as one of several previous studies on the subject which were short term and uncontrolled. In fact, our study did include a well matched control group of patients with asthma who had not previously received corticosteroids. Furthermore, the median duration of treatment among the asthmatic subjects in our study who were receiving high dose inhaled corticosteroids was three years. lution of pleural effusion after a maximum of three injections of CBP) was seen in 22 of the remaining 24 patients. The side effects were fever (in 50% of patients) usually lasting 2-3 days, and mild or moderate chest pain (32% of patients), both of which were effectively controlled with paracetamol or nonsteroidal anti-inflammatory drugs.
G E PACKE
These data confirm that instillation of CBP without intercostal tube drainage is an effective, simple, and well tolerated method of controlling malignant pleural effusions. Our patients had a longer survival time (mean 7-7 months) than that reported by Villanueva et al, and three are still alive with survival times of 11-3, 9-9, and 5-1 months. Our results are also superior to those of patients treated with talc (1 9 months in patients with low pleural fluid glucose levels and low pH and 5-7 months in patients with high glucose and high pH levels),2 and to those treated with mustine (3-9 months 
